181 related articles for article (PubMed ID: 32007657)
1. Cytology for PD-L1 testing: A systematic review.
Gosney JR; Boothman AM; Ratcliffe M; Kerr KM
Lung Cancer; 2020 Mar; 141():101-106. PubMed ID: 32007657
[TBL] [Abstract][Full Text] [Related]
2. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
3. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
[TBL] [Abstract][Full Text] [Related]
5. A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens.
Bubendorf L; Conde E; Cappuzzo F; Langfort R; Schildhaus HU; Votruba J; Concha-López Á; Esteban-Rodriguez I; Feng J; Devenport J; Boyiddle C; Morris S; Trunzer K; Kerr KM
Cancer Cytopathol; 2020 Dec; 128(12):928-938. PubMed ID: 32721105
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer.
Wang G; Ionescu DN; Lee CH; Hiruki T; Myers R; Shaipanich T; Lam S; Melosky B; Zhou C
Lung Cancer; 2019 Oct; 136():1-5. PubMed ID: 31421256
[TBL] [Abstract][Full Text] [Related]
7. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G
BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471
[TBL] [Abstract][Full Text] [Related]
8. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.
Russell-Goldman E; Kravets S; Dahlberg SE; Sholl LM; Vivero M
Cancer Cytopathol; 2018 Apr; 126(4):253-263. PubMed ID: 29405663
[TBL] [Abstract][Full Text] [Related]
9. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
[TBL] [Abstract][Full Text] [Related]
10. Cell-blocks are suitable material for programmed cell death ligand-1 immunohistochemistry: Comparison of cell-blocks and matched surgical resection specimens in lung cancer.
Pak MG; Roh MS
Cytopathology; 2019 Nov; 30(6):578-585. PubMed ID: 31209979
[TBL] [Abstract][Full Text] [Related]
11. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
12. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of Cytologic vs Histologic Specimens for Assessment of Programmed Cell Death Ligand-1 Expression in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Tajarernmuang P; Aliaga F; Alwakeel AJ; Tavaziva G; Turner K; Menzies D; Wang H; Ofiara L; Benedetti A; Gonzalez AV
Chest; 2024 Feb; 165(2):461-474. PubMed ID: 37739030
[TBL] [Abstract][Full Text] [Related]
14. Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer.
Bozzetti C; Squadrilli A; Nizzoli R; Lagrasta C; Gasparro D; Majori M; Filippo M; Becchi G; Azzoni C; Campanini N; Pedrazzi G; Zavani A; Silini EM; Tiseo M; Gnetti L
Immunotherapy; 2020 Feb; 12(3):183-193. PubMed ID: 32066299
[No Abstract] [Full Text] [Related]
15. Higher concordance of PD-L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma.
Mansour MSI; Seidal T; Mager U; Dobra K; Brunnström H; Dejmek A
Cancer Cytopathol; 2021 Jun; 129(6):468-478. PubMed ID: 33493383
[TBL] [Abstract][Full Text] [Related]
16. Program death ligand-1 immunocytochemistry in lung cancer cytological samples: A systematic review.
Satturwar S; Girolami I; Munari E; Ciompi F; Eccher A; Pantanowitz L
Diagn Cytopathol; 2022 Jun; 50(6):313-323. PubMed ID: 35293692
[TBL] [Abstract][Full Text] [Related]
17. Utility of PD-L1 immunocytochemistry using body-fluid cell blocks in patients with non-small-cell lung cancer.
Song SG; Lee J; Koh J; Kim S; Chung DH; Jeon YK
Diagn Cytopathol; 2020 Apr; 48(4):291-299. PubMed ID: 31930724
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC.
Lau SCM; Rabindranath M; Weiss J; Li JJN; Fung AS; Mullen D; Alshamlan N; Ruff HM; Tong LCB; Pal P; Cabanero MR; Hsu YR; Sacher AG; Shepherd FA; Liu G; Bradbury PA; Yasufuku K; Czarnecka-Kujawa K; Mi Ko H; Tsao MS; Leighl NB; Schwock J
Lung Cancer; 2022 Sep; 171():42-46. PubMed ID: 35907387
[TBL] [Abstract][Full Text] [Related]
19. Scoring of Programmed Death-Ligand 1 Immunohistochemistry on Cytology Cell Block Specimens in Non-Small Cell Lung Carcinoma.
Hernandez A; Brandler TC; Chen F; Zhou F; Xia Y; Zhong J; Moreira AL; Simms A; Sun W; Wei XJ; Simsir A
Am J Clin Pathol; 2020 Sep; 154(4):517-524. PubMed ID: 32589185
[TBL] [Abstract][Full Text] [Related]
20. Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
Sinclair W; Kobalka P; Ren R; Beshai B; Lott Limbach AA; Wei L; Mei P; Li Z
Diagn Cytopathol; 2021 Feb; 49(2):219-225. PubMed ID: 33104298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
